Citations

Showing 10 of 108104 citations.

Ultrasound-Guided Cubital Tunnel Decompression in a Collegiate Swimmer: A Case Report
Boettcher, Brennan J. , Finnoff, Jonathan T.

Mayo Clinic

Clinical Journal of Sport Medicine | October 9, 2018 | Volume: 30 | Issue: 1 | Pages: e15-e17

10.1097/jsm.0000000000000680 | PMID 30300144 Get It

Abstract: A 19-year-old female collegiate swimmer presented to our sports medicine clinic with a history and physical examination consistent with right ulnar neuropathy at the cubital tunnel. Diagnostic ultrasound (US) revealed compression of the ulnar nerve under the cubital tunnel retinaculum (CTR) with nerve swelling proximal to the site of compression. Electrodiagnostic studies confirmed the diagnosis of a moderate to severe ulnar neuropathy at the elbow. Treatment consisted of an US-guided decompression of the ulnar nerve in the cubital tunnel by cutting the CTR using a rotated stylet “v” cutting technique. The patient's symptoms resolved, and she was able to begin a swimming progression 2 weeks after the procedure. After completion of this progression, she was able to successfully resume full, unrestricted competitive collegiate swimming without return of her symptoms. To the best of our knowledge, this is the first description of an US-guided cubital tunnel decompression surgery.
‘The shoulders, clavicles, chest and thighs melt away’: a compilation of reviews on cachexia
Laird, Barry , Jatoi, Aminah

Mayo Clinic

Current Opinion in Supportive & Palliative Care | October 9, 2018 | Volume: 12 | Issue: 4 | Pages: 393

10.1097/spc.0000000000000399 | PMID 30300156 Get It

Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma
Henke, Lauren E. , Pfeifer, John D. , Baranski, Thomas , DeWees, T.A. , Grigsby, Perry W. , DeWees, Todd, DeWees, Todd A

Mayo Clinic

Endocrine Connections | October 9, 2018 | Volume: 7 | Issue: 12 | Pages: 1226-1235

10.1530/ec-18-0264 | PMID 30352402 Get It

The majority of papillary thyroid carcinoma (PTC) cases comprise classic papillary (C-PTC) and follicular variant (FV-PTC) histologic sub-types. Historically, clinical equivalency was assumed, but recent data suggest C-PTC may have poorer outcomes. However, large single-institution series with long-term outcomes of C-PTC and FV-PTC, using modern pathologic criteria for FV-PTC, are needed. Our objective was to compare prevalence and impact of clinicopathologic factors, including BRAF mutation status, on long-term outcomes of C-PTC and FV-PTC. We hypothesized that patients with C-PTC would have higher risk disease features and worse survival outcomes. This retrospective study included 1293 patients treated at a single, US academic institution between 1943 and 2009 with mean follow-up of 8.6 years. All patients underwent either partial or total thyroidectomy and had invasive C-PTC or FV-PTC per modern pathology criteria. Primary study measurements included differences in recurrence-free survival (RFS), disease-specific survival (DSS) and associations with clinicopathologic factors including the BRAF mutation. Compared to FV-PTC, C-PTC was associated with multiple features of high-risk disease ( P < 0.05) and significantly reduced RFS and DSS. Survival differences were consistent across univariate, multivariate and Kaplan–Meier analyses. BRAF mutations were more common in C-PTC ( P = 0.002). However, on Kaplan–Meier analysis, mutational status did not significantly impact RFS or DSS for patients with either histologic sub-type. C-PTC therefore indicates higher-risk disease and predicts for significantly poorer long-term outcomes when compared to FV-PTC. The nature of this difference in outcome is not explained by traditional histopathologic findings or by the BRAF mutation.
Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis
Yoon, Harry H. , Shi, Qian , Heying, Erica N., Murányi, Andrea , Bredno, Joerg , Ough, Faith , Djalilvand, Azita, Clements, June, Bowermaster, Rebecca, Shanmugam, Kandavel , Shi, Qian , Liu, Wen-Wei, Barnes, Michael, Alberts, Steven R. , Sinicrope, Frank A.

Mayo Clinic

Clinical Cancer Research | October 9, 2018 | Volume: 25 | Issue: 1 | Pages: 125-133

10.1158/1078-0432.ccr-18-1984 | PMID 30301825 Get It

Abstract Purpose: Colorectal cancers with deficient DNA mismatch repair (dMMR) are presumed to uniformly have dense lymphocytic infiltration that underlies their favorable prognosis and is critical to their responsiveness to immunotherapy, as compared with MMR-proficient (pMMR) tumors. We examined T-cell densities and their potential heterogeneity in a large cohort of dMMR tumors. Experimental Design: CD3+ and CD8+ T-cell densities were quantified at the invasive margin (IM) and tumor core (CT) in 561 stage III colon cancers (dMMR, n = 278; pMMR, n = 283) from a phase III adjuvant trial (N0147). Their association with overall survival (OS) was determined using multivariable Cox analysis. Results: Although CD3+ and CD8+ T-cell densities in the tumor microenvironment were higher in dMMR versus pMMR tumors overall, intertumoral heterogeneity in densities between tumors was significantly higher by 30% to 88% among dMMR versus pMMR cancers (P &lt; 0.0001 for all four T-cell subtypes [CD3+IM, CD3+CT, CD8+IM, CD8+CT]). A substantial proportion of dMMR tumors (26% to 35% depending on the T-cell subtype) exhibited T-cell densities as low as that in the bottom half of pMMR tumors. All four T-cell subtypes were prognostic in dMMR with CD3+IM being the most strongly prognostic. Low (vs. high) CD3+IM was independently associated with poorer OS among dMMR (HR, 4.76; 95% confidence interval, 1.43–15.87; P = 0.0019) and pMMR tumors (P = 0.0103). Conclusions: Tumor-infiltrating T-cell densities exhibited greater intertumoral heterogeneity among dMMR than pMMR colon cancers, with CD3+IM providing robust stratification of both dMMR and pMMR tumors for prognosis. Potentially, lower T-cell densities among dMMR tumors may contribute to immunotherapy resistance.
Response by Kapplinger et al to Letter Regarding Article, “Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation”
Kapplinger, Jamie D., Tester, David J. , Ackerman, Michael J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 9, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circgen.118.002176 | PMID 29752402 Get It

Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation
Kapplinger, Jamie D., Larson, Nicholas B. , Callis, Thomas E. , Tester, David J. , Bikker, Hennie, Wilde, Arthur A.M. , Ackerman, Michael J. , Pundi, Krishna N, Larson, Nicholas B , Pundi, Krishna

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 9, 2018 | Volume: 11 | Issue: 2 | Pages: No page available

10.1161/circgen.116.001424 | PMID 29453246 Get It

Background: Pathogenic RYR2 variants account for ≈60% of clinically definite cases of catecholaminergic polymorphic ventricular tachycardia. However, the rate of rare benign RYR2 variants identified in the general population remains a challenge for genetic test interpretation. Therefore, we examined the results of the RYR2 genetic test among patients referred for commercial genetic testing and examined factors impacting variant interpretability. Methods: Frequency and location comparisons were made for RYR2 variants identified among 1355 total patients of varying clinical certainty and 60 706 Exome Aggregation Consortium controls. The impact of the clinical phenotype on the yield of RYR2 variants was examined. Six in silico tools were assessed using patient- and control-derived variants. Results: A total of 18.2% (218/1200) of patients referred for commercial testing hosted rare RYR2 variants, statistically less than the 59% (46/78) yield among clinically definite cases, resulting in a much higher potential genetic false discovery rate among referrals considering the 3.2% background rate of rare, benign RYR2 variants. Exclusion of clearly putative pathogenic variants further complicates the interpretation of the next novel RYR2 variant. Exonic/topologic analyses revealed overrepresentation of patient variants in exons covering only one third of the protein. In silico tools largely failed to show evidence toward enhancement of variant interpretation. Conclusions: Current expert recommendations have resulted in increased use of RYR2 genetic testing in patients with questionable clinical phenotypes. Using the largest to date catecholaminergic polymorphic ventricular tachycardia patient versus control comparison, this study highlights important variables in the interpretation of variants to overcome the 3.2% background rate that confounds RYR2 variant interpretation.
Unraveling the Puzzle of the Role of Heritability in the Variability of the QT Interval Using Exome Array Analysis
Bos, J. Martijn , Pereira, Naveen L. , Bos, Johan M

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 9, 2018 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/circgen.117.002007 | PMID 29874183 Get It

AMS‐800 Artificial urinary sphincter in female patients with stress urinary incontinence: A systematic review
Peyronnet, B. , O’Connor, Eabhann , Khavari, Rose , Capon, G. , Allué, Marta , Hascoët, J. , Νitti, Victor W. , Gamé, X. , Gilleran, Jason , Castro-Sader, L., Cornu, Jean‐Nicolas , Waltregny, David , Ahyai, Sascha , Chung, Eric , Elliott, Daniel S. , Fournier, Georges , Brucker, Benjamin M. , Peyronnet, Benoit , Cornu, Jean-Nicolas , Manunta, Andrea Fabio

Mayo Clinic

Neurourology and Urodynamics | October 9, 2018 | Volume: 38 | Issue: S4 | Pages: No page available

10.1002/nau.23833 | PMID 30298943 Get It

Aims To perform a systematic review of studies reporting the outcomes of AMS‐800 artificial urinary sphincter (AUS) implantation in female patients with stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). Methods A systematic literature search of the Medline and Embase databases was performed in June 2018 in accordance with the PRISMA statement. No time limit was used. The protocol was registered in PROSPERO (CRD42018099612). Study selection and data extraction were performed by two independent reviewers. Results Of 886 records screened, 17 were included. All were retrospective or prospective non‐comparative case series. One study reported on vaginal AUS implantation, 11 on open AUS implantation, two on laparoscopic AUS implantation, two on robot‐assisted AUS implantation and one compared open and robot‐assisted implantations. The vast majority of patients had undergone at least one anti‐incontinence surgical procedure prior to AUS implantation (69.1‐100%). The intraoperative bladder neck injury rates ranged from 0% to 43.8% and the intraoperative vaginal injury rates ranged from 0 to 25%. After mean follow‐up periods ranging from 5 to 204 months, the complete continence rates ranged from 61.1% to 100%. The rates of explantation, erosion and mechanical failure varied from 0% to 45.3%, 0% to 22.2% and 0% to 44.1%, respectively. Conclusions AMS‐800 AUS can provide excellent functional outcomes in female patients with SUI resulting from ISD but at the cost of a relatively high morbidity. High level of evidence studies are needed to help better define the role of AUS in the female SUI armamentarium.
Review: update on the management of calciphylaxis
Brandenburg, Vincent, Sinha, Smeeta , Nigwekar, Sagar U. , Seethapathy, Harish Shanthanu , el‐Azhary, Rokea A.

Mayo Clinic

QJM: An International Journal of Medicine | October 9, 2018 | Volume: 112 | Issue: 1 | Pages: 29-34

10.1093/qjmed/hcy234 | PMID 30304522 Get It